Skip to main content
. 2015 May-Jun;9(5-6):179–187. doi: 10.5489/cuaj.2618

Table 1.

Baseline demographics of study patients

Factors Open Robotic p value
Age, years N 643 331 <0.001
Mean (SD) 61.49 (7.07) 59.71 (7.03)
First elevated PSA N 432 195 <0.001
Mean (SD) 7.58 (5.22) 5.89 (3.28)
BMI N 597 299 <0.001
Mean (SD) 28.6 (4.0) 27.3 (3.6)
Non response rate 7.2% 9.7%
CCS* 0 512 (80) 289 (87) 0.004
≥1 131 (20) 42 (13)
Biopsy Gleason score N (%)** Low/intermediate risk: Gleason 4, 5, 6, or 7 532 (88) 310 (99) <0.001
High risk: Gleason 8, 9, 10 76 (12) 4 (1)
Ethnicity*** Caucasian: n(%) 228 (75) 98 (63) 0.008
Non-Caucasian: n(%) 75 (25) 58 (37)
PORPUS-P score N 437 210 0.024
Mean (sd) 82.59 (11.10) 84.73(11.26)
Nerve-sparing status None: n (%) 155 (25) 19 (7) <0.001
Unilateral: n (%) 146 (23) 45 (15)
Bilateral: n (%) 326 (52) 224 (78)

Data are shown only for statistically significantly different characteristics. PORPUS-P: Patient-Oriented Prostate Utility Scale-Psychometric; PSA: prostate-specific antigen; CCS: Charlson comorbidity score; SD: standard deviation; RARP: robot-assisted radical prostatectomy; ORP: open radical prostatectomy.

*

All Charlson comorbidities are not captured in the PCDB. The following are captured: myocardial infarction, congestive heart failure, peripheral vascular disease, liver disease, diabetes mellitus, leukemia, lymphoma, AIDS, cerebrovascular Disease, dementia, pulmonary disease, rheumatologic disease, and peptic ulcer.

**

Missing biopsy Gleason scores: n = 35 ORP, n = 17 RARP.

***

Missing ethnicity: n = 340 ORP, n = 175 RARP.